HEX17(Neumifil): An intranasal respiratory biotherapeutic with broad-acting antiviral activity
Open Access
- 22 June 2024
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 228, 105945
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Broadly neutralizing antibodies to combat influenza virus infectionAntiviral Research, 2023
- Loss of life expectancy due to respiratory infectious diseases: findings from the global burden of disease study in 195 countries and territories 1990–2017Journal of Population Research, 2022
- Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019eClinicalMedicine, 2021
- New antibody-based prevention and treatment options for influenzaAntiviral Research, 2019
- Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled studyEBioMedicine, 2019
- Toward antiviral therapy/prophylaxis for rhinovirus‐induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategiesReviews in Medical Virology, 2015
- The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease—A systematic reviewJournal of Clinical Virology, 2014
- Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat modelAntiviral Research, 2013
- Upper Respiratory InfectionsPrimary Care: Clinics in Office Practice, 2013
- A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assaysAntiviral Research, 2009